Peptide Therapy in 2026: What Beverly Hills Patients Need to Know About the Science, the Access, and the Non-Negotiable Role of Physician Supervision

Interest in peptide therapies has grown, but peptides are not a single treatment category with shared benefits or risks. Some peptide-based medicines have established, FDA-approved uses. Many compounds marketed for longevity, injury recovery, or general wellness have much less human evidence. The success of an approved medicine such as semaglutide does not validate unrelated peptide products.

At My Concierge MD in Beverly Hills, Dr. David Nazarian, a board-certified internal medicine physician, provides consultations about peptide therapy and other treatment options. An informed discussion should address the exact product, intended use, evidence, risks, and legal availability.

What Peptide Research Can Tell Us

Peptides are short chains of amino acids. Some act as signaling molecules in the body, and researchers investigate their roles in metabolism, hormone pathways, and tissue responses. Findings in cells or animals are useful for developing hypotheses, but they do not establish that a treatment improves symptoms, recovery, or lifespan in people.

For each proposed treatment, ask whether there are controlled human studies in patients with your condition, whether benefits are clinically meaningful, and what is known about adverse effects and long-term use. Popularity, publication counts, and testimonials do not answer those questions.

Regulatory Changes Require Compound-Specific Verification

FDA approval, eligibility for compounding, and consideration by an advisory committee are different things. Compounded drugs are not FDA-approved. A public announcement about possible policy changes does not, by itself, authorize a product or establish its safety and effectiveness.

FDA’s April 22, 2026 update reported that nominations for several substances, including BPC-157, had been withdrawn and identified plans for further advisory review. Removal from Category 2 because a nomination was withdrawn is not the same as FDA approval or automatic placement in Category 1. Any treatment decision requires verification of the current rules for the exact substance, formulation, and route.

Examples of Peptides That Need Careful Evidence Review

CJC-1295 and ipamorelin: These compounds have been studied for effects on growth hormone pathways. That does not establish their combination as a proven longevity protocol or demonstrate improvements in recovery, sleep, or long-term health. FDA identifies limited clinical data and safety concerns for CJC-1295 and safety concerns for certain compounded peptide products.

Sermorelin: Historical use or approval for a particular indication does not establish the effectiveness or safety of a compounded product for healthy aging. Product-specific status, the intended indication, and appropriate alternatives need separate review.

BPC-157: Much of the tissue-repair research is preclinical. Human evidence is limited, and FDA notes insufficient safety information for proposed routes of administration. It should not be described as an established treatment for injuries, inflammation, or recovery after surgery.

GHK-Cu: Research involving skin or topical applications cannot be assumed to establish the safety and effectiveness of injectable or systemic use. Evidence must match the proposed formulation, route, and treatment goal.

What Physician Supervision Does—and Does Not—Establish

A medical assessment can identify diagnoses, contraindications, medication interactions, and appropriate testing. Monitoring may help identify adverse effects. However, physician supervision does not make an unapproved drug approved, make an otherwise impermissible product lawful, or compensate for missing clinical evidence.

Products sold as research chemicals are not a substitute for appropriately prescribed medicines. Patients should not use an online discussion or a marketing page as instructions to inject an investigational compound. For any legally prescribed medicine suitable for home use, follow the product-specific instructions and training from the treating clinician.

Who Should Seek an Evaluation?

Fatigue, sleep problems, changes in body composition, and poor recovery can have many causes. They do not, on their own, diagnose a growth hormone deficiency or establish a need for peptide treatment. Evaluation should begin with symptoms and medical history, followed by appropriate testing and consideration of established treatments.

To discuss your concerns and available options, contact My Concierge MD at 9301 Wilshire Boulevard, Suite 405A, Beverly Hills, or call (310) 299-8959. A consultation is an opportunity to compare benefits, risks, uncertainties, and alternatives; it does not guarantee eligibility for a particular medicine.

Primary Sources

FDA: Bulk drug substances nominated for compounding under Section 503A; FDA: Potential safety risks of certain compounded substances; FDA: Concerns with unapproved GLP-1 drugs.

Medically reviewed by David Nazarian, MD on September 28, 2026